| 產(chǎn)品編號(hào) | bs-1968R-BF350 |
| 英文名稱 | Rabbit Anti-KLK14/BF350 Conjugated antibody |
| 中文名稱 | BF350標(biāo)記的激肽釋放酶14抗體 |
| 別 名 | Kallikrein 14; kallikrein-related peptidase 14; hK14; Kallikrein-like protein 6; KLK-L6; KLKL6; GK14; MGC157618. |
| 規(guī)格價(jià)格 | 100ul/2980元 購買 大包裝/詢價(jià) |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 信號(hào)轉(zhuǎn)導(dǎo) 激酶和磷酸酶 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Rat, (predicted: Human, Mouse, Dog, Cow, Horse, ) |
| 產(chǎn)品應(yīng)用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 25/29kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human KLK14 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: The human tissue Kallikrein gene family encodes 15 serine proteases. All Kallikreins share structural similarities including cysteine residues, a catalytic triad of His, Asp and Ser residues, typically five coding exons, and varied intron phases. Kallikreins are predominantly secreted as inactive zymogens prior to activation by cleavage of an N-terminal peptide and all function extracellularly. Kallikreins can be activated autocatalytically, via other Kallikreins, or additional proteases. While structurally similar, Kallikrein family members have distinct functions and have key roles in many physiological and pathological processes. Many human tissue Kallikreins also show promise as cancer biomarkers, which may facilitate earlier detection and characterization of many forms of cancer. Kallikrein 14, also known as kallikrein-like6 (KLK-L6), is a trypsin-like serine proteinase. Kallikrein 14 was discovered by cloning the kallikrein locus on chromosome 19 and was found to be similar to the other kallikrein family genes. Kallikrein 14 is produced by a number of tissues, including the brain, spinal cord, esophagus, salivary gland, breast, prostate, uterus, lung, thymus and thyroid. Like many of the kallikreins, Kallikrein 14 is also found in biological fluids like serum, breast milk, amniotic fluid, seminal plasma and cerebrospinal fluid. Kallikrein 14 message has been reported to be decreased in some breast cancers and in ovarian cancers, similar to Kallikrein 10. Some cell lines express Kallikrein 14 in culture and like many of the kallikreins, the production is stimulated by hormones. Recombinant kallikrein 14 was profiled on peptide substrates and found to possess both trypsin-like and chymotrypsin-like activity. The ECM proteins lamanin and collagen-IV are thought to be substrates of Kallikrein 14. Endogenous inhibitors include kallistatin, protein-C inhibitor and alpha1-proteinase inhibitor, although Kallikrein 14 can be found complexed to a number of different proteinase inhibitors. Subunit: Interacts directly with BAK1, BID, BMF and BBC3 (By similarity). Interacts directly with BCL2L11/BIM. Interacts with BAX isoform Sigma. Subcellular Location: Secreted, extracellular space. Tissue Specificity: "Highly expressed in CNS, bone marrow and fetal liver. Similarity: Belongs to the Bcl-2 family. Database links: Entrez Gene: 43847 Human Entrez Gene: 317653 Mouse Omim: 606135 Human SwissProt: Q9P0G3 Human SwissProt: Q8CGR5 Mouse Unigene: 283925 Human Unigene: 247377 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. KLK14目前認(rèn)為在宮頸鱗癌和腺癌中都有表達(dá),是很有意義的標(biāo)志物。激肽釋放酶KLK是激肽系統(tǒng)的主要限速酶，它是一組存在于多數(shù)組織和體液中的絲氨酸蛋白酶，是一種肽鏈內(nèi)切酶。KLK又稱血管舒緩素，包括15個(gè)家族成員。在不同的組織中廣泛表達(dá),具有蛋白水解酶的活性。它特異性的在碳末端切割底物肽，可裂解激肽原釋放具有活性的激肽，由激肽發(fā)揮對(duì)心血管系統(tǒng)及腎臟功能的調(diào)節(jié)作用。 |
